The acquisition of Faubel represents an exciting opportunity for CCL Industries Inc. to further diversify its offerings and tap into the growing demand for pharmaceutical clinical trials labeling. As the healthcare industry continues to evolve, the need for specialized labeling solutions for clinical trials is on the rise. By bolstering its presence in this space, CCL Industries is positioning itself to meet the evolving needs of its customers, which include global corporations, government institutions, small businesses, and consumers.
Moreover, the acquisition aligns with CCL’s broader strategy to strengthen its position as a global leader in providing a wide range of products and solutions to multinational customers across various sectors. The inclusion of Faubel’s expertise and capabilities is expected to contribute significantly to CCL’s operational capacity and market reach.